Applied NeuroSolutions is a specialty biopharmaceutical company that is developing unprecedented early diagnostic tests and therapeutics for Alzheimer’s disease. The company’s technological platform is based on the pioneering scientific work of the company’s scientists that has identified an Alzheimer’s disease-associated protein, named tau, which has been shown to be correlated with the disease’s progression. The company has developed a tau-based cerebrospinal fluid diagnostic test for Alzheimers, which has been shown to positively identify the disease in 85% to 95% of patients while discriminating against other neurodegenerative diseases. The company is also developing targeted therapeutics that inhibit the abnormal tau biological pathway associated with Alzheimer’s. Currently Alzheimer’s can only be conclusively diagnosed postmortem and there are no available drugs that can arrest the progression of the disease, giving the company a pivotal place in the Alzheimer’s market which is currently $148 billion in US health care cost annually.